Tagged with Pricing

Pharma Olivier Laureau, President of the Servier Group, discusses how Servier´s economic model is based on considerable investments in R&D to provide for a better future and on a strong international footprint; and how their ambition is to grow from total revenues of 4 billion euros (4.46 billion USD) today, to…

Pharma After choosing Egypt as the first country to host a production plant in the Middle East, AstraZeneca is interested in strengthening its foothold in the market. The country president discusses the challenges the company is facing as well as the initiatives in place to increase market access and affordability. Could…

Pharma Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what he sees as the keys to unlocking Italy’s potential for innovation over the next few years. Having worked for Amgen…

Pharma Dr. Ermano Buratti, General Manager for Astellas Pharma in Italy, discusses the company’s evolution as it enters its second decade, the importance of partnering with the government on reimbursement, the current state and need for change in the country’s healthcare system, and his efforts to put Astellas in a position…

Pharma Yvonne van Rooy, president of the NVZ, explains the patient’s increasing role as a partner in Dutch healthcare and how greater investment in ICT is needed for the patient to fulfill this role. She further discusses the need for more transparency in the pharmaceutical industry and highlights the need for all stakeholders in the industry to…

Pharma Anita Atema, General Manager of Celgene, reveals Celgene’s inspiring and concrete  initiatives that illustrate how a true willingness to cooperate with healthcare stakeholders and a remarkable effort of transparency can help to tackle the current difficulties in accessing the Dutch market, while implementing new innovative pricing models such as pay for benefit.…

Pharma The Managing Director of MSD Egypt highlights MSD’s unique incentives to further collaborate with the Egyptian medical community and explains how market peculiarities shape product launches in developing countries like Egypt. As newly appointed Managing Director for MSD Egypt, could you please outline your objectives and ambitions in the Egyptian…

Pharma Deputy Minister of Health for Pharmaceutical Affairs Tarek Salman discusses how pharmaceutical regulation in Egypt is taking a leap forward, with the introduction of new legislation with parallel registration process that will bring approval timelines under 21 months, and the imminent establishment of the Egyptian Drug Authority, which will merge…

pharma With almost thirty years of experience in the life sciences sector, local Dutch consultancy firm Baggerman Farma Consult offers a wide portfolio of services to its clients in the pharmaceutical and life sciences industry to meet all of their regulatory needs. Kees Baggerman, CEO and founder, highlights the new Gateway…

Pharma The president of HAS sheds light on the seemingly complex French healthcare system, explains HAS’ role within that context and provides an honest assessment of the system’s advantages and flaws. He also discusses the issues of maintaining the sustainability of the French healthcare budget and the importance of increasing European…

pharma Professor Paul Smits, Dean and Vice Chairman of Radboud University Medical Center in the Netherlands, shares his insights into the strengths of the country’s research climate and the challenges posed by the increasingly high cost of innovative drugs on the healthcare budget. Prof. Smits highlights the benefits that could be…

pharma As Director of the Netherlands’ association for innovative medicines, Gerard Schouw outlines new strategies to enhance the Dutch research climate; foster greater collaboration between all stakeholders and improve public perception of the industry. In light of the upcoming Dutch Presidency of the European Union, the Netherlands intends to lead the…